Intravitreal Bevacizumab for Refractory Pseudophakic Cystoid Macular Edema The Pan-American Collaborative Retina Study Group Results

Arevalo, J. Fernando; Maia, Mauricio; Garcia-Amaris, Rafael A.; Roca, Jose A.; Sanchez, Juan G.; Berrocal, Maria H.; Wu, Lihteh

doi:https://doi.org/10.1016/j.ophtha.2009.04.006

Ítem

Solo Metadatos

Intravitreal Bevacizumab for Refractory Pseudophakic Cystoid Macular Edema The Pan-American Collaborative Retina Study Group Results

https://repository.urosario.edu.co/handle/10336/26147
https://doi.org/10.1016/j.ophtha.2009.04.006

Autores

Arevalo, J. Fernando

Maia, Mauricio

Garcia-Amaris, Rafael A.

Roca, Jose A.

Sanchez, Juan G.

Berrocal, Maria H.

Wu, Lihteh

Fecha

2009-06-22

Editor

Elsevier

Buscar en:

Métricas alternativas

Abstract

Objective: To determine the feasibility, safety, and clinical effect of intravitreal (IVT) bevacizumab (Avastin; Genentech, Inc., San Francisco, CA) in patients with refractory cystoid macular edema (CME) after cataract surgery. Design: Interventional, retrospective, multicenter study.

Keywords

Aged , Aged , 80 and over , Angiogenesis Inhibitors , Antibodies , Monoclonal , Antibodies , Monoclonal , Humanized , Bevacizumab , Cataract Extraction , Feasibility Studies , Female , Fluorescein Angiography , Follow-Up Studies , Humans , Injections , Macular Edema , Male , Postoperative Complications , Pseudophakia , Retrospective Studies , Tomography , Optical Coherence , Treatment Outcome , Vascular Endothelial Growth Factor A , Visual Acuity , Vitreous Body